Stay updated on Pfizer Press Releases
Sign up to get notified when there's something new on the Pfizer Press Releases page.

Latest updates to the Pfizer Press Releases page
- Check3 days agoChange DetectedAdded a dedicated Press Release Archive page and removed the Press Releases and News navigation options, restructuring how press content is accessed.SummaryDifference0.4%

- Check11 days agoChange DetectedAdds four March 2026 press releases to the archive and removes older January–February 2026 entries.SummaryDifference8%

- Check18 days agoChange DetectedAdded Research and Research and Pipeline categories and included the March 17, 2026 press release Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer. Removed Finance and Financial categories and deleted the February 3 conference call webcast entry from December 2025.SummaryDifference2%

- Check25 days agoChange DetectedAdded a March 9, 2026 press release titled Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis under the Research category. Removed the December 17, 2025 press release ‘PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility’ from the archive.SummaryDifference2%

- Check32 days agoChange DetectedAdded the PADCEV™ + Keytruda® press release dated 02.27.2026 under Medicines and Research and Pipeline; added the corresponding category links. Removed the December 16, 2025 press release 'Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance' from the archive.SummaryDifference1%

- Check39 days agoChange DetectedTwo new press releases have been added to the archive: 'Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference' (02.23.2026) and 'U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer' (02.24.2026). Older items were removed: 'TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer' (12.10.2025) and 'Pfizer Declares First-Quarter 2026 Dividend' (12.12.2025).SummaryDifference3%

Stay in the know with updates to Pfizer Press Releases
Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.